Edwards Lifesciences EW has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

This was the stock's second consecutive day of losses.

Edwards Lifesciences’ EW first-quarter 2025 performance was backed by its most comprehensive structural heart disease portfolio. In the TTMT (Transcatheter Mitral and Tricuspid Therapies ...

This was the stock's third consecutive day of losses.

Edwards Lifesciences recently celebrated the FDA approval of its SAPIEN 3 TAVR therapy for asymptomatic aortic stenosis patients, a significant development in cardiac care. This milestone ...

With a market cap of $44.3 billion, Edwards Lifesciences Corporation (EW) provides products and technologies to treat advanced cardiovascular diseases internationally. The company’s product ...

Bill Baruch, founder & president at Blue Line Capital, joins CNBC’s 'Halftime Report' to detail his latest buy.

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 4.27%, which means the company has less short interest than most of its peers. Did ...

IRVINE, Calif., May 06, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...